StockNYSE · US · USDHealthcare · Diagnostics & Research
$A
AGILENT TECHNOLOGIES, INC.
Agilent provides instruments, software, services and consumables for laboratory workflows in life sciences, diagnostics and applied markets. It serves pharmaceutical and biopharmaceutical companies, clinical and life sciences researchers, diagnostic laboratories, academic and government organizations, and customers in areas including chemicals, food, environmental testing and forensics. Agilent is headquartered in Santa Clara, California. Agilent has three business segments. Life Sciences and Diagnostics Markets provides analytical and cell-analysis tools, pathology and genomics products, companion diagnostic development, biomolecular analysis, and contract development and manufacturing services for pharmaceutical customers. Agilent CrossLab offers laboratory services, consumables, software and informatics, and laboratory automation. Applied Markets supplies instruments and software for analyzing the physical and biological properties of substances and products. Agilent sells primarily through direct sales, as well as distributors, resellers, manufacturers’ representatives and electronic commerce.
Jim Cramer on Mad Money criticized big tech companies like Alphabet, Amazon, and Meta, calling them 'millstones' and instead favoring life sciences suppliers. He highlighted Thermo Fisher Scientific (TMO), Agilent Technologies (A), and Waters (WAT) as new tech leaders, citing strong performance and FDA support. TMO is up 20.5% YTD, A up 28.9%, and WAT up 22.1%. Cramer awaits more confirmation before re-entering tech, noting recent NASDAQ-100 decline.
Agilent Technologies (NYSE:A) completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash, with up to $30 million in additional payments tied to future performance milestones. Proscia is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The acquisition adds a recurring-revenue software business to Agilent’s pathology portfolio. Agilent generated $6.95 billion in revenue in fiscal year 2025.
Agilent Technologies (NYSE: A) launched the 5987A MSD with GC Assist, a single quadrupole mass selective detector. The system offers up to 25% faster scan speed, improved dynamic range, and 40% lower energy consumption. It integrates with Agilent's 8890B or 8860B gas chromatograph and MassHunter 14 software to enhance data quality and efficiency. The company aims to help laboratories manage workloads and resources more effectively.
via TradingView
A sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning A (AGILENT TECHNOLOGIES, INC.). Coverage has skewed bullish: 3 bullish, 3 neutral, and 0 bearish.
Recent A coverage spans mergers & acquisitions, financial news and technology.
What's driving A
Guidance raise may support modest price appreciation.
The deal expands Agilent's life‑sciences portfolio and may boost long‑term earnings, but short‑term stock pressure is possible as integration costs are priced in.
AlphAI scores every news story that mentions A with an AI model for sentiment and relevance, and aggregates insider trades from AGILENT TECHNOLOGIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jim Cramer on Mad Money criticized big tech companies like Alphabet, Amazon, and Meta, calling them 'millstones' and instead favoring life sciences suppliers. He highlighted Thermo Fisher Scientific (TMO), Agilent Technologies (A), and Waters (WAT) as new tech leaders, citing strong performance and FDA support. TMO is up 20.5% YTD, A up 28.9%, and WAT up 22.1%. Cramer awaits more confirmation before re-entering tech, noting recent NASDAQ-100 decline.
Agilent Technologies (NYSE:A) completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash, with up to $30 million in additional payments tied to future performance milestones. Proscia is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The acquisition adds a recurring-revenue software business to Agilent’s pathology portfolio. Agilent generated $6.95 billion in revenue in fiscal year 2025.
Agilent Technologies (NYSE: A) launched the 5987A MSD with GC Assist, a single quadrupole mass selective detector. The system offers up to 25% faster scan speed, improved dynamic range, and 40% lower energy consumption. It integrates with Agilent's 8890B or 8860B gas chromatograph and MassHunter 14 software to enhance data quality and efficiency. The company aims to help laboratories manage workloads and resources more effectively.
Agilent Technologies (NYSE: A) agreed to acquire Proscia, a digital pathology software company, for up to $270M. The deal includes $240M upfront and $30M in performance-based payments. Proscia's software integrates AI tools and manages digital tissue images, serving over 4,000 labs and 16 top pharmaceutical firms. The acquisition aims to expand Agilent's presence in the $5B pathology market, combining its diagnostic instruments with Proscia's software.
Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.
Datacor acquired MySep to expand its engineering software portfolio. Agilent Technologies agreed to buy Proscia for up to $270M to enhance digital pathology. Payward, parent of Kraken, will acquire Saldo Bank to expand European banking infrastructure. Terms for the latter two deals were not disclosed.
JPMorgan raised its price target for Agilent Technologies to $195 from $190. UBS also increased its target to $180 from $165. Agilent's stock is up 1.34% year-to-date and 26.11% over 5 days.
Agilent Technologies, a California-based lab tech company, reported 9% year-on-year revenue growth in China, driven by pharmaceutical and food markets. The company's senior executive highlighted China's role in its global supply chain and innovation network, emphasizing the importance of stable US-China relations for long-term collaboration. Agilent plans to expand local manufacturing and research in China over the next few years.
UBS raised its price target for Agilent Technologies (NYSE:A) to $180 from $165. The company agreed to acquire Proscia Inc. for $270 million. Agilent's stock is currently trading at $170.68, up 25.67% year-to-date.
Agilent Technologies (A) agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. The deal is expected to close in the second half of 2023.
